At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MDGL Madrigal Pharmaceuticals
Not Yet Opened 05-12 16:00:00 EDT
510.26
+13.23
+2.66%
盘后510.26
+0.000.00%
19:48 EDT
High511.11Low490.13Vol235.03K
Open494.06D1 Closing497.03Amplitude4.22%
Mkt Cap11.76BTradable Cap5.61BTotal Shares23.06M
T/O118.21MT/O Rate2.14%Tradable Shares11.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals
Simply Wall St.  ·  05-11 10:12
A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline Deals
How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors
Simply Wall St.  ·  05-09
How Blockbuster Rezdiffra Sales and ARO‑PNPLA3 Licensing Will Impact Madrigal Pharmaceuticals (MDGL) Investors
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
TIPRANKS  ·  05-08
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
Madrigal grants inducement equity awards to 47 new employees under 2025 plan
Reuters  ·  05-08
Madrigal grants inducement equity awards to 47 new employees under 2025 plan
Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Dow Jones  ·  05-07
Madrigal Pharmaceuticals Is Maintained at Outperform by Evercore ISI Group
Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
TIPRANKS  ·  05-07
Truist Financial Sticks to Its Buy Rating for Madrigal Pharmaceuticals (MDGL)
Madrigal Pharmaceuticals Inc : Clear Street Raises Target Price to $680 From $533
THOMSON REUTERS  ·  05-07
Madrigal Pharmaceuticals Inc : Clear Street Raises Target Price to $680 From $533
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
TIPRANKS  ·  05-07
Madrigal Pharmaceuticals reports Q1 EPS ($3.25), consensus ($4.14)
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)
TIPRANKS  ·  05-07
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (MDGL) and Pennant Group (PNTG)
BUZZ-Madrigal Pharma rises after Q1 revenue beat
Reuters  ·  05-06
BUZZ-Madrigal Pharma rises after Q1 revenue beat
Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion
Stock Track  ·  05-06
Stock Track | Madrigal Pharmaceuticals Soars 7.44% in Pre-market on Strong Q1 Earnings Beat and Pipeline Expansion
Madrigal Pharmaceuticals Price Target Maintained With a $620.00/Share by HC Wainwright & Co.
Dow Jones  ·  05-06
Madrigal Pharmaceuticals Price Target Maintained With a $620.00/Share by HC Wainwright & Co.
Madrigal's Q1 product revenue jumps 127%, net loss widens on higher costs
Reuters  ·  05-06
Madrigal's Q1 product revenue jumps 127%, net loss widens on higher costs
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss
MT Newswires Live  ·  05-06
Earnings Flash (MDGL) Madrigal Pharmaceuticals Posts Q1 Net Loss $3.25 a Share, vs. FactSet Est of $4.23 Loss
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate
Benzinga  ·  05-06
Madrigal Pharmaceuticals Q1 EPS $(3.25) Beats $(3.60) Estimate, Sales $311.337M Beat $302.268M Estimate
BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million
Reuters  ·  05-06
BRIEF-Madrigal Pharmaceuticals Q1 Product Revenue USD 311.337 Million
Madrigal Pharmaceuticals Inc: Mgl-2086 (Oral Glp-1) Phase 1 Trial on Track to Initiate in 2Q26
THOMSON REUTERS  ·  05-06
Madrigal Pharmaceuticals Inc: Mgl-2086 (Oral Glp-1) Phase 1 Trial on Track to Initiate in 2Q26
Madrigal Pharmaceuticals Q1 EPS USD 3.25
THOMSON REUTERS  ·  05-06
Madrigal Pharmaceuticals Q1 EPS USD 3.25
Madrigal Pharmaceuticals Q1 Operating Expenses USD 404.06 Million
THOMSON REUTERS  ·  05-06
Madrigal Pharmaceuticals Q1 Operating Expenses USD 404.06 Million
Madrigal Pharmaceuticals Q1 Net Income USD -94.391 Million
THOMSON REUTERS  ·  05-06
Madrigal Pharmaceuticals Q1 Net Income USD -94.391 Million

Introduction

Company Name.
Madrigal Pharmaceuticals
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.
Issue price:
--